scholarly journals Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival

2020 ◽  
Vol 9 (8) ◽  
pp. 2502
Author(s):  
Sonja Levy ◽  
Linde M. van Veenendaal ◽  
Catharina M. Korse ◽  
Emilie C.H. Breekveldt ◽  
Wieke H.M. Verbeek ◽  
...  
Keyword(s):  
Small Intestine ◽  
Neuroendocrine Tumours ◽  
Primary Tumour ◽  
Multivariable Analysis ◽  
Unmet Need ◽  
Treatment Strategies ◽  
Risk Groups ◽  
Unknown Primary ◽  
Ki 67 ◽  
Unknown Primary Tumour

Neuroendocrine tumours of the small intestine (SI-NETs) are rare and heterogeneous. There is an unmet need for prognostication of disease course and to aid treatment strategies. A previously developed nomogram based on clinical and tumour characteristics aims to predict disease-specific survival (DSS) in patients with a SI-NET. We aimed to validate the nomogram and identify predictors of survival. Four hundred patients with a grade 1 or 2 SI-NET were included, between January 2000 and June 2016. Predicted 5- and 10-year survival was compared to actual DSS. Multivariable analysis identified predictors for actual DSS. We found that in low-, medium- and high-risk groups 5-year nomogram DSS vs. actual DSS was 0.86 vs. 0.82 (p < 0.001), 0.52 vs. 0.71 (p < 0.001) and 0.26 vs. 0.53 (p < 0.001), respectively. Ten-year nomogram DSS vs. actual DSS was 0.68 vs. 0.69 (p < 0.001), 0.40 vs. 0.50 (p < 0.001) and 0.20 vs. 0.35 (p < 0.001), respectively. Age, WHO-performance score of 2, Ki-67 index ≥10, unknown primary tumour, CgA > 6x ULN and elevated liver tests were identified as independent predictors for a worse DSS. This shows that the nomogram was able to differentiate, but underestimated DSS for patients with a SI-NET. Improvement of prognostication incorporating new emerging biomarkers is necessary to adequately estimate survival.

Primary versus secondary nature of mesenteric neuroendocrine tumours

2021 ◽  
Vol 14 (2) ◽  
pp. e239217
Author(s):  
Ariel Park ◽  
Alicia Martin ◽  
Ramos Carlos ◽  
Vladimir Neychev
Keyword(s):  
Neuroendocrine Tumours ◽  
Single Photon ◽  
Primary Tumour ◽  
Photon Emission ◽  
The Body ◽  
Neuroendocrine Cells ◽  
Unknown Primary ◽  
Emission Computed Tomography ◽  
Unknown Primary Tumour ◽  
Pet Ct

Neuroendocrine tumours (NETs) are rare group of malignancy that originate from neuroendocrine cells present throughout the body. Most patients with NET first present with symptoms associated with metastasis, and up to 20% of patients have unknown primary site of tumour. Most common metastatic sites for small intestine NETs (SI-NETs) are the locoregional lymph nodes and liver. Although mesenteric metastasis through direct extension or lymphatic spread from SI-NETs is common, mesenteric extranodal involvement is extremely rare, and its biology and primary versus secondary nature are not well understood. Due to their small size and location, SI-NETs are frequently undetected on anatomical imaging or indium-111-pentetreotide single-photon emission computed tomography/CT (Octreoscan) and are difficult to be found via endoscopy. Gallium-68-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-octreotate positron emission tomography (68Ga-DOTATATE PET)/CT has been increasingly used for accurate staging, unknown primary tumour site localisation and appropriate management planning. We present a case of an incidentally found mesenteric NET with occult SI-NETs localised preoperatively by 68Ga-DOTATATE PET/CT.

Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis

Endocrine ◽  
2019 ◽  
Vol 64 (3) ◽  
pp. 456-468 ◽  
Author(s):  
Sara De Dosso ◽  
Giorgio Treglia ◽  
Mariarosa Pascale ◽  
Adriana Tamburello ◽  
Prasanna Santhanam ◽  
...  
Keyword(s):  
Detection Rate ◽  
Neuroendocrine Tumours ◽  
Meta Analysis ◽  
Primary Tumour ◽  
Somatostatin Receptor ◽  
Unknown Primary ◽  
Unknown Primary Tumour ◽  
Pet Ct

The Unknown Primary Tumour Presenting as Metastatic Spinal Cord Compression

2013 ◽  
Vol 13 (9) ◽  
pp. S129
Author(s):  
Nasir A. Quraishi ◽  
Sakthivel Rajan Rajaram Manoharan ◽  
Georgios Arealis ◽  
Hossein Mehdian ◽  
Bronek M. Boszczyk
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Compression ◽  
Primary Tumour ◽  
Cord Compression ◽  
Metastatic Spinal Cord Compression ◽  
Unknown Primary ◽  
Unknown Primary Tumour

scholarly journals Lymph Node Metastases in the Neck from Unknown Primary Tumour

1992 ◽  
Vol 31 (6) ◽  
pp. 653-655 ◽  
Author(s):  
John Jakobsen ◽  
Pia Aschenfeldt ◽  
Jørgen Johansen ◽  
Karsten Jørgensen
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastases ◽  
Primary Tumour ◽  
Unknown Primary ◽  
Unknown Primary Tumour ◽  
Node Metastases

scholarly journals The unknown biology of the unknown primary tumour: a literature review

2003 ◽  
Vol 14 (2) ◽  
pp. 191-196 ◽  
Author(s):  
A.J. van de Wouw ◽  
R.L.H. Jansen ◽  
E.J.M. Speel ◽  
H.F.P. Hillen
Keyword(s):  
Literature Review ◽  
Primary Tumour ◽  
Unknown Primary ◽  
Unknown Primary Tumour

Detection of unknown primary neuroendocrine tumors (CUP-NET) using 68Ga DOTA-NOC receptor PET/CT

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4599-4599
Author(s):  
D. Hörsch ◽  
V. Prasad ◽  
V. Ambrosini ◽  
M. Hommann ◽  
S. Fanti ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Primary Tumour ◽  
Unknown Primary ◽  
Low Grade ◽  
Pet Ct ◽  
Pancreatic Net ◽  
The Mean ◽  
Standardised Uptake Values ◽  
F 33

4599 Background: This bi-centric study aimed at determining the role of receptor PET/CT using 68Ga-DOTA-NOC in the detection of undiagnosed primary sites of neuroendocrine tumours (NETs). Methods: Overall 59 patients (M: F 33:26, age 65±9 yr) with documented NET and unknown primary, were enrolled. PET/CT was performed after injection of approximately 100 MBq (46–260 MBq) of 68Ga-DOTA-NOC. The maximum standardised uptake values (SUVmax) were calculated and compared with SUVmax in known pancreatic NET (pNET) and ileum / jejunum / duodenum (SI-NET). The results of PET/CT were also correlated with CT alone. Results: In 35/59 (59%) of patients, 68Ga-DOTA-NOC PET/CT localised the site of the primary: ileum/jejunum (14), pancreas (16), rectum (2), lungs (2) and paraganglioma (1). CT alone (on retrospective analyses) confirmed the findings in 12/59 (20%) patients. The mean SUVmax of identified previously unknown pNET and SI-Net were 18.6 ± 9.8 (range 7.8–34.8) and 9.1± 6.0 (range 4.2–27.8), respectively. SUVmax in patients with previously known pNET and SI-NET were 26.1± 14.5 (range 8.7–42.4) and 11.3±3.7 (range 5.6- 17.9). The SUVmax of the unknown pNET and SI-NET were significantly lower (p< 0.05) as compared to the ones with known primary tumour sites. 19% of the patients had high grade, and 81% low grade NET. In 4/59 patients the primary tumour was subsequently resected (2 pancretic, one ileal and one rectal tumour). Conclusions: Our data indicate that 68Ga- DOTA-NOC PET/CT is highly superior to 111In Octreoscan (17% detection rate for CUP according to literature) and can play a major role in the management of patients with CUP-NET. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document